Bacteriophage strain capable of producing a lytic infection in the
The present invention relates to a bacteriophage strain capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone. The burden of ST131-025b:H4 Escherichia coli clonal complex in human community and hospital-acquired infections is increasing worldwide, going along with a worrying and growing resistance to betalactams and fluoroquinolones. Bacteriophage LM33_P1 infects exclusively (100% specificity) 025b E. coli strains with 70% coverage on the two major antibiotic resistant pandemic clonal complexes ST131-025b:H4 and ST69-025b. The inventors evaluated the in vivo activity of bacteriophage LM33_P1 using three different extraintestinal virulence murine models and showed that it infects bacteria in several organs. In particular, the invention relates to a bacteriophage capable of producing a lytic infection in the Escherichia coli ST131-025b:H4 clone comprising a polypeptide corresponding to the bacteriophage tail fiber protein and responsible for the attachment of the bacteriophage to the Escherichia coli ST131-025b:H4 clone.
1. An isolated bacteriophage comprising a polypeptide having an amino acid sequence having at least 95% identity with the amino acid sequence of SEQ ID NO:1 and a genomic sequence having at least 80% of identity with the genomic sequence of LM33-P1 represented by SEQ ID NO: 2, wherein the genomic sequence of the isolated bacteriophage is not the genomic sequence of LM33-P1 represented by SEQ ID NO: 2; wherein the isolated bacteriophage is able to produce a lytic infection in the Escherichia coli clone ST131-O25b:H4.
2. The isolated bacteriophage according to claim 1 in lyophilized form.
3. The isolated bacteriophage according to claim 1 , wherein the isolated bacteriophage comprises a genomic sequence having at least 90% of identity with the genomic sequence of LM33-P1 represented by SEQ ID NO: 2.
4. The isolated bacteriophage according to claim 3 , wherein the isolated bacteriophage comprises a polypeptide having an amino acid sequence having at least 98% identity with the amino acid sequence of SEQ ID NO:1.
5. The isolated bacteriophage according to claim 1 , wherein the isolated bacteriophage comprises a genomic sequence having at least 95% of identity with the genomic sequence of LM33-P1 represented by SEQ ID NO: 2.
6. The isolated bacteriophage according to claim 5 , wherein the isolated bacteriophage comprises a polypeptide having an amino acid sequence having at least 98% identity with the amino acid sequence of SEQ ID NO:1.
7. An isolated lyophilized bacteriophage comprising a polypeptide having an amino acid sequence having at least 95% identity with the amino acid sequence of SEQ ID NO:1 and a genomic sequence having at least 80% of identity with the genomic sequence of LM33-P1 represented by SEQ ID NO: 2; wherein the isolated bacteriophage is able to produce a lytic infection in the Escherichia coli clone ST131-025b:H4.
8. The isolated lyophilized bacteriophage according to claim 7 , which is the bacteriophage strain LM33-P1 deposited at the French National Collection of Microorganisms at the Institut Pasteur under Accession Number CNCM 1-4964 on Apr. 3, 2015.
9. A method of treating an infection caused by an Escherichia coli ST131-O25b:H4 clone in a patient in need thereof comprising administering to the patient a therapeutically effective amount of an isolated bacteriophage comprising a polypeptide having an amino acid sequence having at least 95% identity with the amino acid sequence of SEQ ID NO:1 and a genomic sequence having at least 80% of identity with the genomic sequence of LM33-P1 represented by SEQ ID NO: 2; wherein the isolated bacteriophage is able to produce a lytic infection in the Escherichia coli clone ST131-O25b:H4.
10. The method of claim 9 , wherein the infection is selected from the group consisting of cystic fibrosis, otitis media, keratitis, endophthalmitis, bacteremia, burn wound infection, pneumonia, meningitis, peritonitis, a urinary tract infection, sepsis, nosocomial infection, lung infection, peritonitis, sepsis, and meningitis.
11. The method of claim 9 , wherein the genomic sequence of the administered isolated bacteriophage is not the genomic sequence of LM33-P1 represented by SEQ ID NO: 2.
12. The method of claim 11 , wherein the infection is selected from the group consisting of cystic fibrosis, otitis media, keratitis, endophthalmitis, bacteremia, burn wound infection, pneumonia, meningitis, peritonitis, a urinary tract infection, sepsis, nosocomial infection, lung infection, peritonitis, sepsis, and meningitis.
13. The method of claim 9 , wherein the administered isolated bacteriophage is the bacteriophage strain LM33-P1 deposited at the French National Collection of Microorganisms at the Institut Pasteur under Accession Number CNCM I-4964 on Apr. 3, 2015.
14. The method of claim 13 , wherein the infection is selected from the group consisting of cystic fibrosis, otitis media, keratitis, endophthalmitis, bacteremia, burn wound infection, pneumonia, meningitis, peritonitis, a urinary tract infection, sepsis, nosocomial infection, lung infection, peritonitis, sepsis, and meningitis.
15. The method of claim 9 , wherein the genomic sequence of the administered isolated bacteriophage comprises a genomic sequence having at least 90% of identity with the genomic sequence of LM33-P1 represented by SEQ ID NO: 2.
16. The method of claim 15 , wherein the administered isolated bacteriophage comprises a polypeptide having an amino acid sequence having at least 98% identity with the amino acid sequence of SEQ ID NO:1.
17. The method of claim 9 , wherein the genomic sequence of the administered isolated bacteriophage comprises a genomic sequence having at least 95% of identity with the genomic sequence of LM33-P1 represented by SEQ ID NO: 2.
18. The method of claim 17 , wherein the administered isolated bacteriophage comprises a polypeptide having an amino acid sequence having at least 98% identity with the amino acid sequence of SEQ ID NO:1.
19. The method of claim 16 , wherein the infection is selected from the group consisting of cystic fibrosis, otitis media, keratitis, endophthalmitis, bacteremia, burn wound infection, pneumonia, meningitis, peritonitis, a urinary tract infection, sepsis, nosocomial infection, lung infection, peritonitis, sepsis, and meningitis.
20. The method of claim 18 , wherein the infection is selected from the group consisting of cystic fibrosis, otitis media, keratitis, endophthalmitis, bacteremia, burn wound infection, pneumonia, meningitis, peritonitis, a urinary tract infection, sepsis, nosocomial infection, lung infection, peritonitis, sepsis, and meningitis.